Share

    


Home / Search Results

Search Results

Search Publications

Search Again?

Filter By Content Type

Filter By Topic

January 27, 2021
Optimal care delivery changes from place to place—what works best for one location and patient population may not be ideal for another. The same applies to cancer research. Understanding the needs of your patient population is critical to trial design and implementation. How can you proactively involve your community in cancer research activities? (January 27, 2021)
It is estimated that 66% of rural counties in America have no oncologist and 32 million Americans live in counties without an oncologist. With an aging population and the recent downturn in cancer screening due to the COVID-19 pandemic, the number of people diagnosed with cancer is expected to increase over the next decade. Advanced Practitioners (APs), defined by the Advanced Practitioner Society …
Rockville, MD (January 26, 2021) - The Association of Community Cancer Centers (ACCC) today released its latest CANCER BUZZ podcast episode aimed at arming pharmacists with strategies to help patients manage and adhere to their oral anti-cancer medication regimens. The podcast is produced as part of ACCC’s project: Evaluating Pharmacy Dispensing Models to Help Improve Cancer Care Delivery. More information …
Learn how the entire cancer care team can help in promoting safe oral anti-cancer medication adherence by bridging gaps in patient education, management, and monitoring.
Carla Strom, MLA, speaks with ACCCBuzz about her role as an advocate, how this role has evolved, and why listening to the community's voice early and often in clinical trial development and cancer research is vital.
Rockville, MD - The Association of Community Cancer Centers (ACCC) has been awarded a Platinum 2020 eHealthcare Leadership Award in the category of Best Healthcare Podcast for its podcast, CANCER BUZZ. The annual eHealthcare Awards recognize cutting-edge digital communications teams and projects from healthcare organizations nationwide. CANCER BUZZ is a resource for cancer care professionals that …
Discover what steps cancer programs can take to build trust with patients from marginalized and underrepresented groups and ensure a more equitable and accessible healthcare environment.
The lawsuit, filed on December 4, 2020 asserted that the Most Favored Nation (MFN) Interim Final Rule exceeded the statutory authority provided to CMS and improperly failed to follow required rulemaking procedures.
Learn how the PECaD program at Siteman Cancer Center is decreasing disparities in care by monitoring data, engaging the community, supporting research, and ensuring diverse representation in research.
Access to Care Policy Project Action on many of today’s most pressing public policy issues in oncology are happening at the state and local level. Some of this is because of legislative gridlock at the federal level, although much is due to the enduring notion that healthcare—and particularly cancer care—is best regulated locally. Today, healthcare policy is among the most hotly debated issues in …
Opinion: Don't Undercut Progress Fighting Cancer January 14, 2021 In his op-ed in The Virginian-Pilot, VAHO President Richard M. Ingram, MD, discusses the ramifications of the Most Favored Nation Rule on drug pricing and reimbursement and the devastating impact it would have on local cancer clinics. "Currently, clinics such as mine buy drugs up front, administer medications, and then bill …
OI | Vol. 36, No. 1, 2021 | accc-cancer.org 23 S pencer Cancer Center provides its scattered rural population in east central Alabama a suite of services that match those of comprehensive cancer centers in large urban areas. Located on the main campus of East Alabama Medical Center, the stand-alone facility opened in June 2019. A recognized provider of high-quality holistic cancer care, Spencer …
With the enormous pressures of COVID-19, the ever-increasing complexity of oncology care, and the persistent social factors that lead to medical injustice, it is difficult to think about tackling even one more job. Yet, we must, we can, and we do. Today I want to mention four specific areas that all cancer programs need to be watching, thinking about, and preparing for.
Community Oncology Can Close the Gap in Cancer Research The research program at Highlands Oncology Group This publication is a benefit of membership Association of Community Cancer Centers Vol. 36 | No. 1 | 2021 Association of Community Cancer Centers ISSUES ONCOLOGY This publication is a benefit of membership Association of Community Cancer Centers Vol. 36 | No. 1 | 2021 …
On Dec. 2, 2020, the Centers for Medicare & Medicaid Services (CMS) issued the final rules for the Hospital Outpatient Prospective Payment System (HOPPS or OPPS) for CY 2021.
This is the story of how a large independent practice in northwest Arkansas has nurtured its research program over several decades and is now able to offer patients access to phase I, II, and III trials close to home and their families.
64 accc-cancer.org | Vol 36, No. 1, 2021 | OI action Dignity Health Northridge Hospital Medical Center Northridge, Calif. Delegate Rep: Jill Dickson, RN, MHA Website: dignityhealth.org/socal/locations/northridgehospital/ services/cancer-center Med Center Health, Medical Center of Bowling Green Bowling Green, Ky. Delegate Rep: Aron O’Dell, BSN Website: medcenterhealth.org/service/cancer ACCC …
OI | Vol. 36, No. 1, 2021 | accc-cancer.org 21 Approved Drugs • On Nov. 25, Y-mAbs Therapeutics, Inc. (ymabs.com) announced that the U.S. Food and Drug Administration (FDA) approved Danyelza® (naxitamab-gqgk) in combination with granulocyte- macrophage colony-stimulating factor for the treatment of pediatric patients one year of age and older and adult patients with relapsed or refractory …
As the manager of Wellspring, a cancer resource center located just two miles from Valley Health Cancer Center at Winchester Medical Center in Virginia, I understand the importance of providing holistic care that meets the body, mind, and spiritual needs of our patients.
With the rise of immunotherapies, it is critical to ensure patient safety, as the toxicity profiles of immunotherapy agents are vastly different from traditional cytotoxic chemotherapies.